A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
In this protocol, baculovirus is produced by transient transfection of baculovirus plasmid into Sf9 cells and amplified in a serum-free suspension culture. The supernatant is purified by heparin affinity chromatography and further concentrated by ultracentrifugation. This protocol is useful for the production and purification of baculovirus for gene therapy application.
Baculovirus has traditionally been used for the production of recombinant protein and vaccine. However, more recently, baculovirus is emerging as a promising vector for gene therapy application. Here, baculovirus is produced by transient transfection of the baculovirus plasmid DNA (bacmid) in an adherent culture of Sf9 cells. Baculovirus is subsequently expanded in Sf9 cells in a serum-free suspension culture until the desired volume is obtained. It is then purified from the culture supernatant using heparin affinity chromatography. Virus supernatant is loaded onto the heparin column which binds baculovirus particles in the supernatant due to the affinity of heparin for baculovirus envelop glycoprotein. The column is washed with a buffer to remove contaminants and baculovirus is eluted from the column with a high-salt buffer. The eluate is diluted to an isotonic salt concentration and baculovirus particles are further concentrated using ultracentrifugation. Using this method, baculovirus can be concentrated up to 500-fold with a 25% recovery of infectious particles. Although the protocol described here demonstrates the production and purification of the baculovirus from cultures up to 1 L, the method can be scaled-up in a closed-system suspension culture to produce a clinical-grade vector for gene therapy application.
Baculovirus is primarily used for the production of recombinant proteins and vaccines in lepidopteran Spodoptera fugiperda (Sf)9 insect cells by using recombinant Autographa californica multicapsid nuclear polyhedrosis virus (AcMNPV)1,2,3,4. More recently, it is emerging as a promising vector for gene therapy application5. It is known to have a broad host and tissue tropism, infects both quiescent and proliferating cells, is non-pathogenic, and does not integrate into the host chromosome4,5,6. Moreover, baculovirus can be produced in serum-free suspension culture which is scalable and allows for closed system processing for future clinical production1.
The purity of baculovirus particles is important for achieving effective transduction while minimizing cytotoxicity7,8,9. Baculovirus can be concentrated by ultracentrifugation or tangential flow filtration (TFF) with limited impact on its infectivity. However, these procedures not only concentrate virus particles but also cellular debris and proteins from Sf9 culture, which can be toxic in vitro (personal observation) and may induce inflammation or an immune response when used in vivo. To avoid this, especially when using highly concentrated virus stocks, infectious baculovirus needs to be purified and separated from contaminating particles.
Several methods have been reported for the purification and concentration of baculovirus vectors10,11,12. Of the available approaches, heparin affinity chromatography allows for a single-step high level of purification with the low concentration of contaminating proteins12. The method is based on the identification of heparan sulfate as the receptor for baculovirus13,14. After loading Sf9 cell supernatant onto the column and binding of baculovirus, the column can be washed with physiologic (isotonic) buffer to remove unbound or loosely bound contaminating particles. Since the binding to heparin is reversible, baculovirus particles can be eluted with a high salt buffer, which is diluted immediately to physiologic (isotonic) salt concentration to prevent inactivation by osmotic shock12. Moreover, the production of baculovirus, as well as capture on and elution from the chromatography column, can be performed using a closed-system process which is compatible with current good manufacturing practices (cGMP).
Here, we provide a detailed protocol for the manufacture, purification, and concentration of infectious baculovirus using affinity chromatography and centrifugation. Briefly, we produce baculovirus by transfection of Sf9 cells with a baculovirus plasmid DNA in adherent culture and further expand the infectious baculovirus in serum-free suspension culture. We purify baculovirus using heparin affinity chromatography and use ultracentrifugation as the final step to highly concentrate the vector for gene therapy application.
Access restricted. Please log in or start a trial to view this content.
See Figure 1 for an illustration summarizing the protocol.
1. Purification of Baculovirus Plasmid DNA
2. Production of Baculovirus
3. Preparation of the Chromatography System
4. Purification of Baculovirus Vector
5. Concentration of Baculovirus
6. Titration of Baculovirus
Access restricted. Please log in or start a trial to view this content.
The protocol presented is in a flow diagram (Figure 1). Steps include the transient transfection of Sf9 cells with bacmid DNA to produce baculovirus in adherent culture in a plate, the subsequent amplification in serum-free suspension culture, nuclease treatment and clarification by centrifugation and filtration, and the purification using the heparin affinity chromatography followed by concentration with ultracentrifugation.
Access restricted. Please log in or start a trial to view this content.
The protocol presented here describes the production of baculovirus in Sf9 cells in suspension culture and purification of baculovirus using a heparin affinity chromatography. The parameters used in this protocol maximize the yield and minimize the inactivation of infectious baculovirus. The protocol provided here shows a significantly improved recovery of baculovirus particles as compared to recoveries achieved by others9.
Due to broad host range and tissue tropism, se...
Access restricted. Please log in or start a trial to view this content.
The authors declare no conflict of interest.
This work is supported in part by the Start-Up funding from Cincinnati Children's Research Foundation (CCRF) to M.N. and Innovative Core Grant (ICG) supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1 TR001425. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
Akta Avant 150 | GE Healthcare | 28976337 | Chromatography system |
POROS Heparin 50 µm Column | ThermoFisher Scientific | 4333414 | Heparin column |
Ultracentrifuge | Beckman-Coulter | Non-catalog item | Concentrates virus at high-speed |
Polyallomer Ultracentrifuge tube | Beckman-Coulter | 326823 | Concentrates virus at high-speed |
MaxQ 8000 orbital shaker incubator | ThermoFisher Scientific | Non-catalog item | Shaker for suspension culture |
250 mL Erlenmeyer flasks | ThermoFisher Scientific | 238071 | Flask for suspension culture |
1 L Erlenmeyer flasks | ThermoFisher Scientific | 238072 | Flask for suspension culture |
Microscope (Olympus CKX41) | Olympus | Non-catalog item | Cell monitoring and counting |
Table top centrifuge | ThermoFisher Scientific | 75253839/433607 | For clarification of Baculovirus supernatant |
50 ml Conical tube | ThermoFisher Scientific | 14-959-49A | For collection of Baculovirus supernatant |
6-well plate | ThermoFisher Scientific | 07-200-80 | Tissue culture treated plate |
10-cm plate | ThermoFisher Scientific | 08-772E | Tissue culture treated plate |
Stericup-HV, 0.45 µm, PVDF | EMD-Millipore | SCHVU05RE | Filtration unit |
Kanamycin | ThermoFisher Scientific | 15160-054 | |
Tetracycline | Sigma-Aldrich | T7660 | |
Gentamycin | ThermoFisher Scientific | 15750-060 | |
Bac-to-Bac Vector Kit | ThermoFisher Scientific | 10360-014 | Baculovirus expression system |
DH10B-T1R Competent cell | ThermoFisher Scientific | 12331-013 | Competent cell for bacmid |
TE buffer | In-house | Non-catalog item | 10 mM Tris-HCl, 1 mM EDTA, pH 8.0. |
Plasmid Maxiprep kit | ThermoFisher Scientific | K2100-06 | For bacmid purification |
Sf9 Cells | ThermoFisher Scientific | 11496-015 | Insect cells |
Grace’s Insect Cell Culture Medium | ThermoFisher Scientific | 11605-094 | Transfection medium |
PBS | ThermoFisher Scientific | 20012227 | Washing cells, diluting samples |
HyClone SFX-Insect cell media | GE Healthcare | SH30278.02 | Serum-free insect cell growth medium |
Benzonase Nuclease | Sigma-Aldrich | E1014 | Enzyme to degrade DNA and RNA |
Baculovirus plasmid (bacmid) DNA | In-house | Non-catalog item | Bacmid for Baculovirus Production |
Cellfectin II | ThermoFisher Scientific | 10362 | Transfection reagent for insect cells |
Bovine serum albumin (BSA) | Sigma-Aldrich | A4737 | Stabilizes Baculovirus |
Cryovial | Thomas Scientific | 1222C24 | For storage of Baculovirus |
HT1080 cell line | ATCC | CCL-121 | Fibroblast cell line |
DMEM | Sigma-Aldrich | D6429 | Growth media for cell lines |
Wash buffer | In-house | Non-catalog item | 20 mmol/l phosphate buffer containing 150 mmol/l sodium chloride |
Elution buffer | In-house | Non-catalog item | 20 mmol/l phosphate buffer containing 1.5 mol/l sodium chloride |
Column cleaning buffer | In-house | Non-catalog item | 20 mmol/l phosphate buffer containing 2.0 mol/l sodium chloride |
Sterile water | In-house | Non-catalog item | For Akta Avant cleaning |
Sodium hydroxide | Sigma-Aldrich | 1.09137 | For Akta Avant cleaning |
Ethanol | Sigma-Aldrich | E7073 | For Akta Avant cleaning |
Access restricted. Please log in or start a trial to view this content.
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved